Biocept (NASDAQ:BIOC) and Psychemedics (NASDAQ:PMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.
Psychemedics pays an annual dividend of $0.72 per share and has a dividend yield of 4.2%. Biocept does not pay a dividend.
Earnings & Valuation
This table compares Biocept and Psychemedics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Biocept||$5.07 million||0.51||-$21.61 million||($23.72)||-0.05|
|Psychemedics||$39.70 million||2.36||$6.12 million||N/A||N/A|
Psychemedics has higher revenue and earnings than Biocept.
Institutional and Insider Ownership
10.5% of Biocept shares are owned by institutional investors. Comparatively, 57.4% of Psychemedics shares are owned by institutional investors. 2.6% of Biocept shares are owned by company insiders. Comparatively, 8.6% of Psychemedics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and price targets for Biocept and Psychemedics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Biocept currently has a consensus target price of $1.00, indicating a potential downside of 12.28%. Given Biocept’s higher possible upside, equities analysts plainly believe Biocept is more favorable than Psychemedics.
Risk and Volatility
Biocept has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, Psychemedics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
This table compares Biocept and Psychemedics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Psychemedics beats Biocept on 10 of the 13 factors compared between the two stocks.
Biocept Company Profile
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Psychemedics Company Profile
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.